Licochalcone H Targets EGFR and AKT to Suppress the Growth of Oxaliplatin -Sensitive and -Resistant Colorectal Cancer Cells-Reference-Cited by-同舟云学术

Licochalcone H Targets EGFR and AKT to Suppress the Growth of Oxaliplatin -Sensitive and -Resistant Colorectal Cancer Cells

Published:2023-11-01 Issue:6 Volume:31 Page:661-673
ISSN:1976-9148
Container-title:Biomolecules & Therapeutics
language:en
Short-container-title:Biomol Ther (Seoul)

Author:

Lee Seung-On¹,Lee Mee-Hyun²,Kwak Ah-Won³,Lee Jin-Young⁴,Yoon Goo⁵,Joo Sang Hoon⁶,Choi Yung Hyun⁷,Park Jin Woo¹⁵,Shim Jung-Hyun¹⁵⁸

Affiliation:

1. Department of Biomedicine, Health & Life Convergence Sciences, BK21 Four, College of Pharmacy, Mokpo National University, Muan 58554, Republic of Korea

2. College of Korean Medicine, Dongshin University, Naju 58245, Republic of Korea

3. Biosystem Research Group, Department of Predictive Toxicology, Korea Institute of Toxicology, Daejeon 34114, Republic of Korea

4. Department of Biological Sciences, Keimyung University, Daegu 42601, Republic of Korea

5. Department of Pharmacy, College of Pharmacy, Mokpo National University, Muan 58554, Republic of Korea

6. College of Pharmacy, Daegu Catholic University, Gyeongsan 38430, Republic of Korea

7. Department of Biochemistry, College of Korean Medicine, Dong-Eui University, Busan 47227, Republic of Korea

8. The China-US (Henan) Hormel Cancer Institute, Zhengzhou 450008, China

Funder

National Research Foundation of Korea

Ministry of Science and ICT, South Korea

Publisher

The Korean Society of Applied Pharmacology

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Biochemistry

Link

https://pdf.medrang.co.kr/BT2/2023/031/BT031-06-661.pdf

Reference42 articles.

1. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells

2. KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania

3. Chinese Herbal Medicine Glycyrrhiza inflata Reduces Aβ Aggregation and Exerts Neuroprotection through Anti-Oxidation and Anti-Inflammation

4. Role of oxaliplatin in the treatment of colorectal cancer

5. Ekblad, L. and Johnsson, A. (2012) Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer. Anticancer Res. 32, 783-786.